lymph nodes enlarged/ swelling of lymph nodes; fever within a few hours of vaccine.; fatigue within a few hours of vaccine.; visible lump under arm developed within 24 hours of vaccine (same side as vaccine site); extremely painful; this is a spontaneous report received from a contactable reporter(s) (consumer or other non hcp) from the regulatory agency. regulatory number: gb-mhra-webcovid-202202112037512060-zxcit. other case identifier(s): gb-mhra-adr 26602198. a 30 year-old female patient (not pregnant) received bnt162b2 (comirnaty), administered in arm, administration date 10feb2021 (batch/lot number: unknown) at the age of 30 years as dose 3 (booster), single for covid-19 immunisation. the patient had no relevant medical history. diagnosis of auto-inflammatory condition (not listed above). the patient's concomitant medications were not reported. vaccination history included: bnt162b2 (dose 1, single), for covid-19 immunisation; bnt162b2 (dose 2, single), for covid-19 immunisation. the patient was not enrolled in clinical trial. the patient did not had symptoms associated with covid-19 and not had a covid-19 test. the patient was not pregnant and was not currently breastfeeding. last menstrual date was 17jan2021. patient has not tested positive for covid-19 since having the vaccine. the following information was reported: pyrexia (medically significant) with onset 10feb2021, outcome "not recovered", described as "fever within a few hours of vaccine."; fatigue (medically significant) with onset 10feb2021, outcome "not recovered", described as "fatigue within a few hours of vaccine."; lymphadenopathy (medically significant) with onset 11feb2021, outcome "not recovered", described as "lymph nodes enlarged/ swelling of lymph nodes"; vaccination site mass (medically significant) with onset feb2021, outcome "unknown", described as "visible lump under arm developed within 24 hours of vaccine (same side as vaccine site)"; pain (medically significant) with onset feb2021, outcome "unknown", described as "extremely painful". the events "fever within a few hours of vaccine.", "fatigue within a few hours of vaccine.", "lymph nodes enlarged/ swelling of lymph nodes", "visible lump under arm developed within 24 hours of vaccine (same side as vaccine site)" and "extremely painful" were evaluated at the physician office visit. the patient underwent the following laboratory tests and procedures: body temperature: (10feb2021) fever. therapeutic measures were taken as a result of lymphadenopathy, vaccination site mass, pain. general practitioner (gp) consulted and advised to rest and utilise antihistamine medication and analgesia. this report was not related to possible inflammation of the heart (myocarditis or pericarditis). no follow-up attempts are possible; information about lot/batch number cannot be obtained. no further information is expected